Patients with high-risk localized prostate cancer benefit from multimodality therapy of curative intent. Androgen-deprivation therapy (ADT) combined with radiation improves survival in this population. However, prior clinical trials of neoadjuvant ADT and surgery failed to consistently demonstrate a survival advantage. The development of novel, more potent hormonal agents presents an opportunity to revisit the potential for neoadjuvant therapy to improve long-term outcomes for patients with localized prostate cancer. We review recent advances in neoadjuvant approaches for prostate cancer and emerging clinical trials data supporting the use of neoadjuvant therapy prior to radical prostatectomy.

中文翻译：

---

根治性前列腺切除术之前的新辅助方法。

高危局限性前列腺癌患者受益于多种治疗目的的联合疗法。雄激素剥夺疗法（ADT）与放射线结合可以改善该人群的生存率。然而，新辅助ADT和手术的先前临床试验未能始终证明其生存优势。新型，更有效的激素制剂的开发为重新审视新辅助疗法的潜力提供了机会，以改善局部前列腺癌患者的长期预后。我们回顾了前列腺癌新辅助治疗方法的最新进展以及支持在根治性前列腺切除术之前使用新辅助治疗的临床试验数据。